Large plexiform neurofibroma on right thigh of a farmer in the course of Recklinghausen disease – Case report

Jacek Sompor¹, Andrzej Prystupa², Bartłomiej Wawrzycki³, Katarzyna Wojciechowska⁴, Emilia Kančik⁵, Ewa Kuryś-Denis⁶, Andrzej Ochal¹, Tomasz Prystupa⁶, Mariusz Jojczuk¹, Tomasz Kulesza¹, Halina Antosz⁴

¹ Department of Trauma Surgery and Emergency Medicine, Medical University of Lublin, Poland
² Department of Internal Medicine, Medical University of Lublin, Poland
³ Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Poland
⁴ Department of Clinical Genetics, Medical University of Lublin, Poland
⁵ II Department of Medical Radiology, Medical University of Lublin, Poland
⁶ Students Research Association, Medical University of Lublin, Poland

Abstract

A 59-year-old farmer was admitted to the Department of Trauma Surgery because of pain associated with the presence of a tumour on the side of the right thigh. The patient stated that his biggest problem was great difficulty in moving and handling agricultural machinery due to the aforementioned lesion. On physical examination, the patient presented with numerous cutaneous and subcutaneous neurofibromas, as well as one large plexiform neurofibroma. Diagnosis of Neurofibromatosis type 1 was established, based on National Institutes of Health diagnostic criteria. Moreover, molecular genetic testing found known pathogenic mutation p.Arg1769* in one of the alleles of NF1 gene (heterozygote), typical for Recklinghausen disease. The big plexiform neurofibroma in the patient was not operated on because of lung cancer.

Key words

Recklinghausen disease, Neurofibromatosis type 1, tumour of the right thigh

CASE REPORT

A 59-year-old farmer was admitted to the Department of Trauma Surgery because of pain associated with the presence of a tumour on the side of the right thigh. He also reported decreased exercise tolerance, dyspnoea at rest and progressive weakness. The patient stated that his biggest problem was the great difficulty in moving and handling of agricultural machinery due to the aforementioned lesion. On physical examination, the patient presented with numerous cutaneous and subcutaneous neurofibromas, as well as one large plexiform neurofibroma. The sequence analysis of NF1 gene (heterozygote) typical for Recklinghausen disease. The consulting dermatologist confirmed the nature of the cutaneous lesions as nevofibromas.

Diagnosis of Neurofibromatosis type 1 (NF-1) was established based on National Institutes of Health diagnostic criteria. Moreover, molecular genetic testing found known pathogenic mutation p.Arg1769* in one of the alleles of NF1 gene (heterozygote), typical for Recklinghausen disease. The sequence analysis of NF1 gene (exons 1–58) was performed. Next-generation sequencing (NGS) technology and the next-generation sequencing diagnostic panel were used for exon-level analyses. Additionally, exons 7, 11, 38, 41 and 43 were analyzed by direct sequencing.

The patient had four brothers and one sister, but there was no knowledge of any close relative presenting the symptoms of Neurofibromatosis type 1 in his family. The mutation seemed to have arisen de novo in the patient’s genome.
Because of increased malignancy ratio in NF-1, an additional set of radiological examinations were performed. Abdominal ultrasound showed no abnormalities. Chest X-ray confirmed clinically suspected generalized, pulmonary emphysema and right-sided scoliosis, however with no other significant pathologies. Pelvis X-ray showed a big left-sided vertebral column rotoscoliosis involving a pathological rotation of the pelvis and both femur bones. Developed signs of degenerative bone and sacro-iliac joints disease were also observed. Histopathology of biopsied nodules presented the typical picture of neurofibromas.

The patient also underwent CT of the chest with intravenous contrast administration, which revealed a singular, irregularly outlined tissue area of 15x17 mm localized in the second segment of the right lung, with radially oriented outgrowths extending in the direction of pulmonary parenchyma. The solitary tumour enhanced pathologically after intravenous contrast administration proved to be lung cancer. Additionally, enlarged mediastinal lymph nodes were noted, being in favour of tumour lymph nodes metastasis. Other pathologies included multiple generalized lesions of emphysema and fibrotic changes in the pulmonary parenchyma. The abdominal CT with contrast showed, furthermore, the presence of an unclear, hypodense change in segment IVB of the liver, close to the hepatoumbilical ligament, which was completely invisible to the ultrasound examination. Head MRI did not show any pathological changes.

After pulmonary consultation, the patient was qualified for palliative chemotherapy because of the lung cancer.

**DISCUSSION**

Neurofibromatosis type I (NF-1) is inherited as an autosomal dominant disorder with complete penetrance and variable expression [1]. Birth incidence is 1/500 with a prevalence of 1/4,000 [2]. The NF-1 gene is located at chromosome 17q11.2 and contains 350 kilobases of DNA [3]. It has 60 exons and codes for an 11- to 13-kb transcript with an open reading frame coding for 2,818 amino acids [4].

NF-1 gene encodes neurofibromin, which is a guanosine triphosphatase (GTPase)-activating protein (GAP) that helps maintain the proto-oncogene RAS in an inactive form. Loss of neurofibromin results in increased RAS activity, particularly in neurocutaneous tissues, leading to constitutive downstream signaling increased uncontrolled proliferation and tumourigenesis [6]. Dasgupta et al. [7] suggest that neurofibromin also can positively regulate cyclic adenosine monophosphate (cAMP) levels. Increased cyclic AMP levels are associated with reduced cell growth.

Many different mutations within the NF-1 gene can cause Neurofibromatosis type 1. The mutational spectrum includes nonsense, frameshift, splice mutations, missense and/or small in-frame deletions, and deletions of the entire NF-1 gene [2]. The spontaneous mutation rate of the NF-1 gene is one of the highest known in the human genome, and is approximately 100-fold greater than the average mutation rate [8]. About 5% of patients with Neurofibromatosis type 1 have a deletion of the entire, or nearly entire, NF-1 gene, and these patients display a more severe phenotype [9].

Mutation detection in the NF-1 gene is a complex process due to the size of the gene, the existence of pseudogenes, the lack of clustering of the mutations in a particular region of the gene, and the great variety of possible lesions, such as chromosomal abnormalities, large deletions, microdeletions, insertions, splicing mutations, nonsense and missense mutations. In NF-1 patients, the mutation detection rates rarely exceed 50%. Approximately 50% of all NF-1 patients represent sporadic cases of the disease [10].

Neurofibromas are the most common feature of Neurofibromatosis type 1. Benign nerve sheath tumours consisting of Schwann cells, fibroblasts, perineural cells, and mast cells, may occur on the surface of the skin, along deeper peripheral nerves, and along nerve roots. Some neurofibromas, especially plexiform neurofibromas, may transform into malignant peripheral nerve sheath tumours, the lifetime risk for which is estimated at around 10%. Café-au-lait macules, skin-fold freckling, iris Lisch nodules and melanocytic hamartomas of the iris are nontumor manifestations of NF-1. Patients may have skeletal dysplasias, scoliosis, vascular disease and epilepsy; they may also have learning disabilities, language, reading, visuospatial, neuromotor and concentration problems [11]. The 59-year-old patient in the current case presented symptoms of NF-1.

Diagnosis of Neurofibromatosis type 1 (NF-1) is based on National Institutes of Health (NIH) diagnostic criteria which are as follows: a first degree relative with NF1, six or more café-au-lait patches (>1.5 cm in adults), axillary or groin freckling, two or more neurofibromas or one plexiform neurofibroma, two or more Lisch nodules (iris hamartomas), optic pathway glioma, and distinctive bony lesions (i.e. dysplasia of the sphenoid wing, bowing of the long bone +/- pseudoarthrosis) [12]. Two or more of these criteria are obligatory for a definite diagnosis. After being established, they are validated by several groups, and their utility has been proven in every day clinical practice [13]. Although they are highly specific and sensitive in the adult population, in some children, especially those with no family history of NF-1, the diagnosis can only be presumptive and delayed as many features of NF-1 develop with age [13].

Among a variety of cutaneous manifestations reported in subjects with Neurofibromatosis type 1, the most specific, e.g. café-au-lait macules, axillary/inguinal freckling (Crowe sign) and neurofibromas (dermal or plexiform), are incorporated into the set of diagnostic criteria. Less characteristic and less commonly associated with NF-1 are: increased base pigmentation, juvenile xanthogranuloma, glomus tumour, melanoma, blue-red macules, pseudoatrophic macules and nevus anemicus [14, 15].

As in other autosomal dominant genodermatoses, visible cutaneous signs of the NF-1 (e.g. café-au-lait macules, neurofibromas) are believed to be a result of the bi-allelic inactivation of the NF-1 gene through a ‘second hit’ causing loss of heterozygosity (LOH) [17].

On examination, the patient in the presented case exhibited café-au-lait spots located on the lower and upper extremities, as well as on the trunk, of longest diameter ranging from 1.5–15 cm (Fig. A, B, C, D). The classic café-au-lait spots/macules (CALs/CALMs) are well demarcated macules with smooth borders, of round to oval shape, and homogeneous tan to dark brown colour. They vary in size from 2–20 cm. Café-au-lait macules are randomly distributed, although in opposition to ephelides, unexposed areas of the body are sites of predilection [14, 15].

To meet the criteria, patient needs to present with six or more café-au-lait macules >5 mm in greatest diameter in...
The tumour mass composed of Schwann cells, fibroblasts, mast cells, and perineural cells, forms soft, flesh-coloured to slightly pigmented, dome shaped or sometimes pedunculated nodules and papulo-nodules, with diameter rarely exceeding 3 cm. These lesions do not undergo malignant transformation. In most instances, neurofibromas are asymptomatic; however, irritation and itching sensation may occur [14]. As for subcutaneous neurofibromas, they are usually firmer and less well circumscribed, and in opposition to superficial variant, they may cause tenderness, pain and bear relatively small malignant potential [14].

Neurofibromas start to evolve in the late teens or around prepubertal age, and in majority of patients are fully developed by the age of 20 (48% by 10 years; 84% by 20), although their size and number not only differ greatly among affected individuals but also the extent of the lesions shows intrafamilial variability [17, 18, 19, 20, 21, 22].

Finally, in the presented case, on the fronto-lateral aspect of the patient’s right thigh there was visible large plexiform neurofibroma (PN), hence, along with previously described skin findings, the patient met the criteria necessary to establish diagnosis of NF-1.

In opposition to cutaneous neurofibromas, plexiform neurofibromas are usually congenital; however, only approximately 30% of cases are clinically accessible. Thus, most of the cases remain undetected unless they become apparent on imaging. Plexiform neurofibromas involve multiple nerve fascies and may extend deeply into surrounding tissues causing disfigurement. They develop from birth to the age of 18 years. Superficial forms might be surmounted by hyperpigmented skin or overlaid by hypertrichosis and feel like a ‘bag of worms’ upon palpation. Plexiform neurofibromas also have the potential for malignant transformation into MPNST (Malignant peripheral nerve sheath), which occurs in about 10% of patients [14, 17, 18, 19, 20, 21, 22].

In the presented case, the large plexiform neurofibroma was not operated on because of lung cancer.

CONCLUSIONS

The pathogenic mutation p.Arg1769* in one of the alleles of NF1 gene was the cause of the neurofibromatosis in the presented patient. Neurofibromatosis type 1 is an inherited genetic condition which predisposes to high risk of tumour formation. In this case, the patient exhibited many of the characteristic symptoms of NF-1, most of them in a severe form.

REFERENCES

Large plexiform neurofibroma on right thigh